FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Research analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for RAPT Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($1.51) for the year, up from their prior forecast of ($2.39). The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.43) per share. Leerink Partnrs also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at ($0.33) EPS.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09.

RAPT has been the subject of several other research reports. HC Wainwright raised RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, December 26th. JPMorgan Chase & Co. downgraded shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Wells Fargo & Company dropped their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Stifel Nicolaus restated a “hold” rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Finally, Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $8.00 to $2.00 in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, RAPT Therapeutics has a consensus rating of “Hold” and a consensus target price of $9.56.

RAPT Therapeutics Trading Down 0.9 %

Shares of RAPT Therapeutics stock opened at $1.15 on Monday. The business has a 50-day moving average price of $1.26 and a two-hundred day moving average price of $1.76. RAPT Therapeutics has a 1-year low of $0.79 and a 1-year high of $27.35. The company has a market cap of $40.20 million, a P/E ratio of -0.42 and a beta of 0.03.

Institutional Investors Weigh In On RAPT Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Picton Mahoney Asset Management increased its holdings in RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after acquiring an additional 14,697 shares during the period. JPMorgan Chase & Co. grew its position in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. Readystate Asset Management LP bought a new position in shares of RAPT Therapeutics in the third quarter worth $36,000. Barclays PLC raised its position in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after buying an additional 42,636 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.